A new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed ...

Sanofi secured amlitelimab as part of its $1.1 billion acquisition of Kymab back in 2021. But the writing was already on the wall for the anti-OX40 ligand antibody as far back as September 2025, when ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | AI-focused Formation Bio has found a new chief scientist with ...

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million ...

Scancell Holdings and Neuphoria Therapeutics have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders afte | ...

Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials in different ...

Roche may have scrapped work on a T-cell engager (TCE) for lupus, but the company’s head of pharma told Fierce Biotech that the drugmaker still has a strategy for developing cell therapies for ...

Despite its status as the “pharmacy of the world,” India’s deep life sciences roots have traditionally been based in manufacturing and replication. | A string of recent wins on the frontiers of novel ...

The U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates are celebrating the bill as a step toward a new era in preclinical testing ...

Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch. | Crystalys Therapeutics has ...

"We have long contemplated a U.S. listing and concluded that the company has reached a stage of maturity sufficient to attract the attention of U.S. investors,” Clinuvel’s Chief Operating Officer ...

The FDA has authorized Johnson & Johnson’s Ottava Robotic Surgical System as it looks to compete with Intuitive Surgical and Medtronic. Ottava is now FDA-approved for multiple soft tissue surgeries, ...